Recursion Pharma Names New CMO, Chief Medical Officer Departs
Ticker: RXRX · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel, cmo
Related Tickers: RXRX
TL;DR
New CMO in, old CMO out at Recursion Pharma. Keep an eye on their drug pipeline.
AI Summary
Recursion Pharmaceuticals, Inc. announced on March 15, 2025, the departure of Chief Medical Officer, Dr. Blake W. Johnson. The company also announced the appointment of Dr. Laura A. Perry as the new Chief Medical Officer, effective March 15, 2025. Additionally, the company reported on compensatory arrangements for its named executive officers.
Why It Matters
This filing indicates a leadership change in a key medical role, which could impact the company's drug development strategy and pipeline progression.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in strategy or internal challenges.
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Registrant
- Dr. Blake W. Johnson (person) — Departing Chief Medical Officer
- Dr. Laura A. Perry (person) — Appointed Chief Medical Officer
- March 15, 2025 (date) — Effective date of changes
FAQ
Who is the new Chief Medical Officer at Recursion Pharmaceuticals?
Dr. Laura A. Perry has been appointed as the new Chief Medical Officer, effective March 15, 2025.
Who has departed from Recursion Pharmaceuticals?
Dr. Blake W. Johnson, the former Chief Medical Officer, has departed from Recursion Pharmaceuticals.
When were these changes effective?
The changes, including the appointment of the new CMO and the departure of the previous CMO, were effective as of March 15, 2025.
What other information is provided in this 8-K filing?
The filing also includes information regarding compensatory arrangements for certain officers.
What is Recursion Pharmaceuticals' primary business?
Recursion Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 by Dr. Blake W. Johnson regarding RECURSION PHARMACEUTICALS, INC. (RXRX).